416 related articles for article (PubMed ID: 32647212)
1. Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.
Ogawara H
J Antibiot (Tokyo); 2021 Jan; 74(1):24-41. PubMed ID: 32647212
[TBL] [Abstract][Full Text] [Related]
2. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.
Dickey SW; Cheung GYC; Otto M
Nat Rev Drug Discov; 2017 Jul; 16(7):457-471. PubMed ID: 28337021
[TBL] [Abstract][Full Text] [Related]
3. Novel agents to inhibit microbial virulence and pathogenicity.
Escaich S
Expert Opin Ther Pat; 2010 Oct; 20(10):1401-18. PubMed ID: 20718591
[TBL] [Abstract][Full Text] [Related]
4. Specific Antivirulence Activity, A New Concept for Reliable Screening of Virulence Inhibitors.
Defoirdt T
Trends Biotechnol; 2016 Jul; 34(7):527-529. PubMed ID: 26879186
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial resistance: more than 70 years of war between humans and bacteria.
Nadeem SF; Gohar UF; Tahir SF; Mukhtar H; Pornpukdeewattana S; Nukthamna P; Moula Ali AM; Bavisetty SCB; Massa S
Crit Rev Microbiol; 2020 Sep; 46(5):578-599. PubMed ID: 32954887
[TBL] [Abstract][Full Text] [Related]
6. Disarming pathogens: benefits and challenges of antimicrobials that target bacterial virulence instead of growth and viability.
Totsika M
Future Med Chem; 2017 Mar; 9(3):267-269. PubMed ID: 28207349
[No Abstract] [Full Text] [Related]
7. Anti-virulence strategies to combat bacteria-mediated disease.
Rasko DA; Sperandio V
Nat Rev Drug Discov; 2010 Feb; 9(2):117-28. PubMed ID: 20081869
[TBL] [Abstract][Full Text] [Related]
8. Bacterial fitness shapes the population dynamics of antibiotic-resistant and -susceptible bacteria in a model of combined antibiotic and anti-virulence treatment.
Ternent L; Dyson RJ; Krachler AM; Jabbari S
J Theor Biol; 2015 May; 372():1-11. PubMed ID: 25701634
[TBL] [Abstract][Full Text] [Related]
9. Anti-virulence Strategies to Target Bacterial Infections.
Mühlen S; Dersch P
Curr Top Microbiol Immunol; 2016; 398():147-183. PubMed ID: 26942418
[TBL] [Abstract][Full Text] [Related]
10. Underestimated collateral effects of antibiotic therapy in prosthesis-associated bacterial infections.
Baldassarri L; Montanaro L; Creti R; Arciola CR
Int J Artif Organs; 2007 Sep; 30(9):786-91. PubMed ID: 17918123
[TBL] [Abstract][Full Text] [Related]
11. Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options.
M Campos JC; Antunes LC; Ferreira RB
Future Microbiol; 2020 May; 15():649-677. PubMed ID: 32495702
[No Abstract] [Full Text] [Related]
12. Antivirulence compounds: a future direction to overcome antibiotic resistance?
Buroni S; Chiarelli LR
Future Microbiol; 2020 Mar; 15():299-301. PubMed ID: 32286100
[No Abstract] [Full Text] [Related]
13. Where will new antibiotics come from?
Walsh C
Nat Rev Microbiol; 2003 Oct; 1(1):65-70. PubMed ID: 15040181
[TBL] [Abstract][Full Text] [Related]
14. [Target-specific screening of antivirulence preparations for chronic infection therapy].
Zigangirova NA; Gintsburg AL
Zh Mikrobiol Epidemiol Immunobiol; 2011; (4):107-15. PubMed ID: 21913401
[TBL] [Abstract][Full Text] [Related]
15. Emergence and dissemination of antibiotic resistance: a global problem.
Choudhury R; Panda S; Singh DV
Indian J Med Microbiol; 2012; 30(4):384-90. PubMed ID: 23183460
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic resistance and virulence: Understanding the link and its consequences for prophylaxis and therapy.
Guillard T; Pons S; Roux D; Pier GB; Skurnik D
Bioessays; 2016 Jul; 38(7):682-93. PubMed ID: 27248008
[TBL] [Abstract][Full Text] [Related]
17. [Type III bacterial secretion system, a promising target for the development of a new generation of antibiotic drugs].
Gintsburg AL; Zigangirova NA; Zorina VV
Vestn Ross Akad Med Nauk; 2008; (10):34-9. PubMed ID: 19140396
[TBL] [Abstract][Full Text] [Related]
18. Virulence-targeted Antibacterials: Concept, Promise, and Susceptibility to Resistance Mechanisms.
Ruer S; Pinotsis N; Steadman D; Waksman G; Remaut H
Chem Biol Drug Des; 2015 Oct; 86(4):379-99. PubMed ID: 25589217
[TBL] [Abstract][Full Text] [Related]
19. Quenching the quorum sensing system: potential antibacterial drug targets.
Kalia VC; Purohit HJ
Crit Rev Microbiol; 2011 May; 37(2):121-40. PubMed ID: 21271798
[TBL] [Abstract][Full Text] [Related]
20. Novel approaches to bacterial infection therapy by interfering with cell-to-cell signaling.
Rasko DA; Sperandio V
Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.3. PubMed ID: 19235150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
